Severe mental disorders following anti-retroviral treatment in a patient on peritoneal dialysis: A case report and literature review

Qi-En He, Min Xia, Guang-Hui Ying, Xue-Lin He, Jiang-Hua Chen, Yi Yang

Abstract

BACKGROUND
Antiviral drugs are widely used in populations with viral infection caused by immunologic inadequacy. Because these drugs are mainly metabolized by the kidneys, patients with renal failure undergoing renal replacement therapy are prone to drug adverse effects and poisoning. Severe neurotoxicity caused by antiviral drugs is a rare but life-threatening complication.

CASE SUMMARY
This study reported one male patient on peritoneal dialysis who suffered from severe mental disorders after receiving an overdose of acyclovir and valacyclovir for the treatment of herpes zoster. The literature review suggested that hemodialysis is better than peritoneal dialysis to clear acyclovir from the circulation. The patient died after his consciousness deteriorated despite peritoneal dialysis and continuous blood purification.

CONCLUSION
This case emphasizes cautiousness when using anti-retroviral drugs in patients with uremia. Hemodialysis is optimal method to remove the drugs.

Key words: Chronic renal failure; Peritoneal dialysis; Acyclovir; Valacyclovir; Neurotoxicity; Herpes zoster; Case report

©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
A patient on peritoneal dialysis who received an overdose of anti-virals showed severe mental disorders. Peritoneal dialysis and continuous renal replacement therapy did not improve the symptoms. Hemodialysis is recommended to remove excess drugs.

Citation: He QE, Xia M, Ying GH, He XL, Chen JH, Yang Y. Severe mental disorders following anti-retroviral treatment in a patient on peritoneal dialysis: A case report and literature review. World J Clin Cases 2019; 7(20): 3329-3334

INTRODUCTION

Herpes zoster occurs upon reactivation of varicella zoster virus and is characterized by pain and blistering skin eruption with dermatomal distribution[1-4]. The occurrence of herpes zoster increases with decline in T-cell-mediated immunity, which may occur with age or immunosuppression[1-4]. The rash typically resolves in 2-4 wk, but nerve pain may continue for months to years[1,3]. Beside pain management, anti-retroviral drugs can be used in patients without response to topical anti-retroviral, age ≥ 50 years, moderate to severe pain, severe rash, and/or non-truncal involvement[2,4]. The common drugs include valacyclovir, acyclovir, foscarnet, and bruvudin[2]. Compared with acyclovir, valacyclovir has advantages such as better oral effectiveness and tolerance, high water solubility, and less adverse reactions. Valacyclovir rapidly transforms into acyclovir after entering the body. Its common side effects include nausea, vomiting, and discomfort[5].

One possible, albeit rare, side effect of anti-retroviral drugs is central nervous system toxicity, which has been described since the 1980s[6-9]. The symptoms in patients with previously normal brain function may include visual hallucinations, death delusion, tremor, and coma, with onset of 24-72 h after starting acyclovir[8]. The symptoms are possibly due to a metabolite of acyclovir that is found at high levels in the cerebrospinal fluid of patients with neuropsychiatric symptoms[10]. Since 90% of acyclovir is cleared by the kidneys, patients with chronic kidney disease have increased serum half-life of acyclovir[11]. Most patients with neuropsychiatric disorders under acyclovir treatment have renal function impairment[11].

We present one patient on peritoneal dialysis who suffered from severe mental disorders after taking an overdose of antiviral drugs for herpes zoster. The patient died after his consciousness did not improve after peritoneal dialysis and continuous blood purification.

CASE PRESENTATION

Chief complaints
A 65-year-old man on peritoneal dialysis was referred to our hospital in July 2018 with complaints of blisters on the left frontal area with pain, and unstable walking and hallucinations.

History of present illness
The patient felt severe pain in the left frontal face, with blisters for 6 d, and was diagnosed with herpes zoster. He was given antiviral treatment with intravenous acyclovir 0.5 g qd and dexamethasone 5 mg qd to relieve pain (continuous treatment for 3 d). The dermatologist prescribed oral valacyclovir 0.3 g bid after 3 d. Nonetheless, the patient misunderstood the recommendation, and received acyclovir and valacyclovir simultaneously. After 2 d of treatment, the local facial pain was relieved, and the blisters became stable, but he became with unstable walking and involuntary shaking of the limbs, accompanied by hallucinations (irregular fluttering of objects when the eyes were closed), irritability, and lethargy. He denied fever, loss of consciousness, epilepsy, suicidal or homicidal ideation, and a sudden stop of dialysis. Before onset, the patient had mild temperament and took care of himself in the daily life.

History of past illness
The patient had a history of hypertension for more than 10 years, under control using
nifedipine controlled release tablets 30 mg bid and valsartan 80 mg bid.

He was diagnosed with idiopathic chronic renal failure (stage 5). He had been receiving peritoneal dialysis treatment for 3 years. He was anuric at admission using peritoneal dialysis solution with 2.5% calcium glucose 2000 mL × 4 bags, continuous ambulatory peritoneal dialysis (CAPD), with an ultrafiltration of 1200 mL/d.

Personal and family history
The patient denied any personal or family history of diseases.

Physical examination upon admission
On admission, the body temperature 37.2 °C, pulse 107 bpm, breathing 20/min, blood pressure 175/108 mmHg, intermittent mild disturbance of consciousness, and with visible scattered red blister rash in the left eyelid and left forehead, which was protruded and tender, but otherwise with normal superficial lymph nodes and cardiopulmonary examinations. Nervous system examination showed negative Pap's sign but normal muscle tension in limbs.

Laboratory examinations
The laboratory examinations showed: White blood cells 7.8 × 10^9/L, hemoglobin 86 g/L, albumin 28 g/L, creatinine 1146 µmol/L, urea nitrogen 21.6 mmol/L, uric acid 277 µmol/L, potassium 4.2 mmol/L, sodium 145 mmol/L, PO_4 43 mmHg, TCO_2 24 mmol/L, glucose 4.7 mmol/L, and iPTH 313 pg/mL. Dialysis adequacy: KT/V = 1.64 (1 mo ago), Ccr= 41.4 L/wk. The electrocardiogram showed normal sinR rhythm. The lumbar puncture showed: Cerebrospinal fluid pressure 155 mmH2O, proteins 542 mg/L, glucose 4.64 mmol/L, chlorine 121.7 mmol/L (no abnormality), and negative bacteria and tuberculosis.

Imaging examinations
There were no obvious abnormalities in head and chest computed tomography (CT) as well as head magnetic resonance imaging (MRI).

FINAL DIAGNOSIS
Based on the laboratory test results and imaging examinations, the differential diagnoses of cerebrovascular accidents, viral encephalitis and uremia encephalopathy were ruled out. Since he had a clear history of overdose of antiviral drugs 6 days prior to the onset of the psychiatric symptoms, the patient was finally diagnosed as mental disorders caused by antiviral drugs.

TREATMENT
Immediately after admission, valacyclovir was discontinued, the peritoneal fluid was increased to 5 bags/d, 2000 mL per bag, and CAPD mode, and the blood pressure was dropped to around 150-160/90 mmHg after antihypertensive treatment with Adalat 30 mg bid, valsartan 80 mg bid and perindopril 8 mg qd. After 2 d of treatment, the involuntary limb shaking was not relieved and the disturbance of consciousness progressively aggravated (drowsiness-delirium-coma). On the third day after admission (July 31, 2018), the patient’s respiratory failure worsened, blood gas analysis showed: pH 7.18, PO_2 81 mmHg (oxygen), and PaCO_2 77 mmHg, revealing carbon dioxide retention and type 2 respiratory failure. After intubation and respiratory support, the patient was transferred to the intensive care unit (ICU) on the fourth day after admission. In the ICU, peritoneal dialysis was discontinued and continuous renal replacement therapy (CRRT) was started.

OUTCOME AND FOLLOW-UP
Though given positive rescue treatment, the patient’s consciousness was not improved. The patient died 6 d after admission.

DISCUSSION
Herpes zoster usually develops in patients with compromised immune function. Patients on dialysis are at high risk of Herpes zoster. Both valacyclovir and acyclovir...
are considered to have strong inhibitory effects on types 1 and 2 herpes virus and varicella herpes virus[12]. Valacyclovir is a precursor of acyclovir, which is converted to acyclovir by the liver. Compared with acyclovir, it has the advantages of higher absorption rate, more better pharmacokinetics and pharmacodynamics, and lower frequency of use[9].

The neurotoxicity of acyclovir was reported as early as the 1980s[6-9]. The clinical manifestations include consciousness disorders and hallucinations, fantasy, insomnia, photoallergies, dysarthria, paresthesia, and coma[13-17]. If uremia patients develop neuropsychiatric symptoms during anti-retroviral treatment, it is especially important to promptly identify and discontinue the suspicious drugs. Clinicians tend to overlook drug-induced neuropsychiatric disorders. The patient had a history of excessive use of antiviral drugs and showed obvious neuropsychiatric symptoms, despite normal head CT and MRI, and lumbar puncture and cerebrospinal fluid examination. In the present report, the patient had limb shaking, visual hallucinations, and severe disturbances of consciousness, and these symptoms progressively aggravated, which is very rare.

Valacyclovir-associated neurotoxicity usually occurs within 48-72 h of treatment start, and the symptoms can be gradually relieved after the drug is discontinued for 4-14 d (Table 1). For the patient in the present study, the time of onset and duration of symptoms were similar to those reported in literature[14,15,29] (Table 1).

Since acyclovir is mainly cleared by the kidneys, it is a consensus to reduce its dose in patients with renal failure[21]. The dose is mainly determined by a combination of factors such as different methods of dialysis, residual renal function, hydration, and age. The dose of drug used in many cases of neurotoxicity is often greater than the recommended dose[11,24]. It is generally believed that a concentration of acyclovir of 2.5-4.5 µg/mL[29] or a concentration of its main metabolite, carboxymethoxy methylguanine, above 10.8 µmol/L[24] in plasma leads to neurotoxicity. Nevertheless, there is still no consensus on the specific numerical reference range of therapeutic and toxic doses of such drugs, and it is difficult to measure the drug levels in clinical practice.

In the case reported here, increasing the dose of peritoneal dialysis and retention time still could not alleviate the clinical symptoms. Acyclovir and valacyclovir are both soluble and low-protein-bound drugs. In terms of the effectiveness of valacyclovir, a single hemodialysis for 6 h can remove about 60% of the drug, while it is considered to have poor clearance by peritoneal dialysis. On the other hand, case reports suggested that peritoneal dialysis with continuous perfusion of super-dose peritoneal dialysis solution can promote the clearance of valacyclovir[13,14,21,27]. Studies have shown that in patients with normal renal function, 89% of valacyclovir can be cleared from the urine in the form of acyclovir after 2.5-3.3 h, while the half-life of the drug is extended to 14-20 h in patients receiving CAPD for uremia (4 × 2 L exchange dose), and only 5.27 mL/min (0.355 L/h/1.73 m²) can be cleared by peritoneal dialysis[21,27]. After a 6-h hemodialysis, the hemodialysis clearance rate of acyclovir is up to 113 mL/min and the plasma drug concentration can be reduced by 61.6%. Therefore, hemodialysis is at least 20 times better than peritoneal dialysis in terms of clearance effect. Based on the large differences in clearance rates between the two dialysis methods, it is suggested to switch peritoneal dialysis to hemodialysis to increase the effect of drug clearance[21,24,28]. Nevertheless, when neurotoxicity occurs, the expected improvement of neurotoxicity by hemodialysis may be delayed, even for a few days. Kageyama et al[29] reported a 75-year-old hemodialysis male who presented with hallucinations, dysarthria, and psychotic symptoms after intravenous acyclovir with reduced dose, which further indicates that the dose adjustment of these drugs is difficult and needs to be comprehensively individualized. CRRT has a good effect on clearing drugs with middle-and-large molecular weight or high protein binding rate. Meanwhile, valacyclovir and acyclovir are soluble and have a low protein binding rate, but there is a lack of literature on the efficacy of CRRT in clearing acyclovir and valacyclovir.

**CONCLUSION**

In summary, clinicians need to be extra cautious when applying antiviral drugs in patients with renal failure. They need to be alert to the possible serious neuropsychiatric symptoms, need to adjust dose according to the level of renal function, pay attention to treatment course and hydration, be fully aware of the possible neurotoxicity caused by these drugs, and be aware of the good prognosis after early identification and active intervention. In the meantime, since the clearance rate of these drugs is low when using peritoneal dialysis, these patients should be
| Author                   | Year of publication | Patient sex/age | Stage of CKD                        | Renal replacement manner | Dosage (mg/d) | Duration of antiviral treatment | Concomitant medication                                                                 | Neuropsychiatric symptoms                                                                 | Outcome                                                                 |
|-------------------------|---------------------|-----------------|------------------------------------|--------------------------|---------------|-------------------------------|----------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|--------------------------------------------------------------------------|
| Pipili et al[18]        | 2013                | Female/72       | ESRD                               | PD                       | Valacyclovir tablets 3 g daily for 3 d | 3 d             | Nifedipine, ibrsartan, cinacalcet, atorvastatin, alfalcacidol                         | Confusion and visual hallucinations                                          | 3 d, restored after PD 6 × 2 L per day                                     |
| Chaudhari et al[16]     | 2014                | Male/66         | ESRD                               | PD                       | Oral valacyclovir 1000 mg daily for 7 d | 7 d             | Simvastatin, metoprolol, sevelamer, furosemide, glimepiride                               | Hallucination, insomnia, and photosensitivity                                   | 7 d, improved after regular regimen and hydration                          |
| Asahi et al[17]         | 2009                | Female/78       | Without previous renal failure     | NO                       | Valacyclovir 3000 mg/d                  | 6 d             | Not mentioned                                                                | Unconsciousness                                                             | 5 d, recovered 14 d later                                                  |
| Asahi et al[17]         | 2009                | Male/73         | ESRD                               | Hemodialysis             | Valacyclovir 3000 mg/d                  | 2 d             | Not mentioned                                                                | Confusion, hallucination                                                      | 2 d, completely recovered 3 d later                                        |
| Singh et al[19]         | 2014                | Female/58       | ESRD                               | HD                       | Valacyclovir 500 mg/d                  | 2 d             | Not mentioned                                                                | Altered sensorium, irritability, drowsiness, confusion                        | 2 d, completely recovered 5 d later                                        |
| Kambham-pati et al[20]  | 2011                | Female/49       | ESRD                               | Maintenance hemodialysis | Valacyclovir 1000 mg three times a day | 2 d             | Not mentioned                                                                | Disoriented, confused, agitated, hallucinating, delirious, incoherent        | 1 d, 4000 mg, completely recovered after second session of hemodialysis |
| Prasad et al[14]        | 2017                | Female/57       | ESRD                               | PD                       | 1000 mg three times per day of valacyclovir | 3 d             | Not mentioned                                                                | Confusion and altered sensorium                                              | 1 day, completely recovered 24h later                                     |
| Izzedine et al[21]      | 2001                | Female/60       | ESRD                               | PD                       | Valacyclovir 500 mg daily               | Reduced 500 mg of valacyclovir every 2 d | Not mentioned                                                                | Disoriented with ocular and auditory hallucinations and loss of decorum without torpor or coma. | 3 d, recovered 48 h later                                                  |
| Strumia et al[22]       | 2004                | Male/81         | ESRD                               | Hemodialysis             | Oral valacyclovir 1000 mg every 8 h then intravenous acyclovir in full dosage | 3 d             | Not mentioned                                                                | Visual hallucination, confusion and disorientation                           | 3 days, completely recovered 6 d later                                    |
| Linsens-Schuurmans et al[23] | 1998          | Male/58         | CKD                                | Intermittent hemodialysis twice a week | Valacyclovir 3 g/d                      | 2 d             | Not mentioned                                                                | Dizziness, hallucinations, loss of decorum, disoriented, slurred speech       | 1 d, complete recovery                                                    |
| Takayanagi et al[24]    | 2010                | Male/67         | ESRD                               | PD                       | Valacyclovir, 1 g/d                     | 5 d             | Not mentioned                                                                | Hallucinations                                                              | 7 d, complete recovery                                                    |
| Sadjadi et al[25]       | 2018                | Male/80         | ESRD                               | PD                       | Acyclovir 5 mg/kg intravenously, followed by oral acyclobir 400 mg/d | 3 d             | Not mentioned                                                                | Confusion, delusion, disorientation, restlessness, visual hallucinations, seizures | 2 d, complete recovery                                                    |

CKD: Chronic kidney disease; ESRD: End-stage renal disease; PD: Peritoneal dialysis.
switched to hemodialysis.

REFERENCES

1. Sampathkumar P, Drage LA, Martin DP. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc 2009; 84: 274-280 [PMID: 19252116 DOI: 10.4065/MC00041696[116114-4]

2. Cohen JI. Clinical practice. Herpes zoster. N Engl J Med 2013; 369: 255-263 [PMID: 23863052 DOI: 10.1056/NEJMep1302674]

3. Wilson JF. In the clinic. Herpes zoster. Ann Intern Med 2011; 154: ITCS1-15; quiz ITCS16 [PMID: 21357905 DOI: 10.7326/0003-4819-154-4-201110300-10001]

4. Dworkin RH, Johnson RW, Breuer J, Giann JW, Levin MJ, Backonja M, Betts RF, Gershon AA, Haanpaa ML, McKendrick MW, Nurmiokko TJ, Oaklander AL, Oxman MN, Payan-Langston D, Petersen KL, Rowbotham MC, Schmader KE, Stacey BR, Tying SK, van Wijck AJ, Wallace MS, Wassilew SW, Whalley RJ. Recommendations for the management of herpes zoster. Clin Infect Dis 2007; 44 Suppl 1: S1-26 [PMID: 17143845 DOI: 10.1086/510206]

5. Cernik C, Gallina K, Brodell RT. The treatment of herpes simplex infections: an evidence-based review. Arch Intern Med 2008; 168: 1137-1144 [PMID: 18541820 DOI: 10.1001/archinte.168.11.1137]

6. Wade JC, Meyers JD. Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation. Ann Intern Med 1983; 98: 921-925 [PMID: 6305245]

7. Cohen SM, Minkove JZ, Zebley JW, Mullolland JL. Severe but reversible neurotoxicity from acyclovir. Ann Intern Med 1984; 100: 920 [PMID: 6721312]

8. Tomson CR, Goodship TH, Rodger RS. Psychiatric side-effects of acyclovir in patients with chronic renal failure. Lancet 1985; 2: 385-386 [PMID: 2862353]

9. Vartian CV, Shihes DM. Intravenous acyclovir and neurologic effects. Ann Intern Med 1983; 99: 568 [PMID: 6625395]

10. Helldén A, Odar-Cederlöf I, Diener P, Barkholt L, Medin C, Svensson JO, Säwe J, Ståhle L. High serum concentrations of the acyclovir main metabolite 9-carboxyethylmethoxymethylguanine in renal failure patients with acyclovir-related neuropsychiatric side effects: an observational study. Nephrol Dial Transplant 2003; 18: 1135-1141 [PMID: 12748346]

11. Haeefel WE, Schoneenberger RA, Weiss P, Ritz RF. Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose. Am J Med 1993; 94: 212-215 [PMID: 8430717]

12. Lin WR, Lin HH, Lee SS, Tsai HC, Huang CK, Wann SR, Chen YS, Chang SC, Yen MY, Liu YC. Comparative study of the efficacy and safety of valacyclovir versus acyclovir in the treatment of herpes zoster. J Microbiol Immunol Infect 2001; 34: 138-142 [PMID: 11456360]

13. Okada T, Nakao T, Matsumoto H, Nagaoka Y, Iwasawa H, Nanni K, Yamakazi T. Valacyclovir neurotoxicity in a patient with end-stage renal disease treated with continuous ambulatory peritoneal dialysis. Clin Nephrol 2002; 58: 168-170 [PMID: 12227892]

14. Prasad B, McIsaac M, Toppings J. Valacyclovir-associated neurotoxicity treated with intensification of peritoneal dialysis. BMJ Case Rep 2017; 2017: bcr-2017-220678 [PMID: 28765478 DOI: 10.1136/bcr-2017-220678]

15. Olin JL, Gugliotta JL. Possible valacyclovir-related neurotoxicity and aseptic meningitis. Ann Pharmacother 2003; 37: 1814-1817 [PMID: 14673709 DOI: 10.1345/aph.1e1217]

16. Chaudhari D, Ginn D. Valacyclovir-associated neurotoxicity in peritoneal dialysis patients. Am J Ther 2014; 21: e215-e217 [PMID: 23528373 DOI: 10.1097/MTJ.0b013e318289bae9]

17. Asahi T, Tsutsumi M, Wakanui K, Tange D, Takahashi C, Tokui K, Okawa S, Okadera H. Valacyclovir neurotoxicity: clinical experience and review of the literature. Eur J Neurol 2009; 16: 457-460 [PMID: 19187228 DOI: 10.1111/j.1468-1331.2008.02527.x]

18. Pipili C, Pantelias K, Dedh E, Tsiamalos P, Kostis E, Grapsa E. Intensification of peritoneal dialysis improves valacyclovir neurotoxicity. Ren Fail 2013; 35: 289-290 [PMID: 23176110 DOI: 10.1109/0886002x.2012.743914]

19. Singh NP, Shah HR, Aggarwal N, Jha LJ, Behura S. Valacyclovir associated neurotoxicity in a patient on dialysis. Indian J Nephrol 2014; 24: 128-129 [PMID: 24701050 DOI: 10.4103/0971-4065.127915]

20. Kambhampati G, Pukkinkavena U, Kazory A. Valacyclovir neurotoxicity can be effectively managed by hemodialysis. Eur J Neurol 2011; 18: e33 [PMID: 21087359 DOI: 10.1111/j.1468-1331.2010.03250.x]

21. Izzedine H, Mercadal I, Aymard G, Lauzney-Vacher V, Martinez V, Issad B, Deray G. Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study. Am J Nephrol 2001; 21: 162-164 [PMID: 11359026 DOI: 10.1159/000046241]

22. Strumia S, De Mitri P, Bionda E. Neurotoxicity of acyclovir and valacyclovir in a hemodialysis patient. Eur J Neurol 2004; 11: 68-69 [PMID: 14692893]

23. Linsen-Schuermans CD, van Kan EJ, Feith GW, Uges DR. Neurotoxicity caused by valacyclovir in a patient on hemodialysis. Ther Drug Monit 1998; 20: 385-386 [PMID: 9712461]

24. Takayanagi A, Maezuma T, Kyojo Y, Yamase M. Neurotoxicity of valacyclovir in a peritoneal dialysis patient. Hinyokika Kiyo 2010; 56: 617-619 [PMID: 21187705]

25. Sadja SA, Regmi S, Chau T. Acyclovir Neurotoxicity in a Peritoneal Dialysis Patient: Report of a Case and Review of the Pharmacokinetics of Acyclovir. Am J Case Rep 2018; 19: 1459-1462 [PMID: 30531673 DOI: 10.12699/ajcr.01520]

26. Feldman S, Rodman J, Gregory B. Excessive serum concentrations of acyclovir and neurotoxicity. J Infect Dis 1988; 157: 385-388 [PMID: 3333515]

27. Stathoulopoulos F, Dhillon S, Thodiis H, Stathakis C, Vargemezis V. Evaluation of valaciclovir dosage reduction in continuous ambulatory peritoneal dialysis patients. Nephron 2002; 91: 164-166 [PMID: 12021536 DOI: 10.1159/000057621]

28. Takayanagi A, Hashimoto J, Adachi H, Hirota H. Two patients with neurotoxicity caused by over-dose of antiviral drugs during hemodialysis therapy. Jpn J Clin Neurol 2006; 60: 581-583

29. Kageyama R, Hashizume H. Neurotoxicity induced by the recommended acyclovir dosing in a dialysis patient with herpes zoster: A case letter. J Dermatol 2016; 43: 339-340 [PMID: 26589129 DOI: 10.1111/1346-8138.13196]
